.

Legal Developments in the World of Trademarks, Copyrights, Advertising, and Beyond

Advertising

Comparative Advertising Do's and Don'ts from the NAD - Part 2

December 5, 2016

by Sandra Edelman

Download as a PDF

Share this page

simparicaLast week we blogged about a recent decision of the National Advertising Division of the Better Business Bureau, holding that two YouTube videos for Rayovac brand batteries misleadingly communicated an unsupported "line" claim of superiority against all Energizer batteries. This post will discuss a second decision issued by NAD a few days later, also finding comparative advertising to be misleading. The problem this time? The product testing conducted by the advertiser on which the advertising claims were based failed to evaluate the performance of the competitive products in accordance with the manufacturer instructions for use. Zoetis, Inc. (Case # 6013 Oct. 31, 2016).

Zoetis made claims on its website and in print advertising that its Simparica brand oral flea and tick medication for dogs provided better protection than the competitive Trifexis product marketed by the Elanco Animal Health division of Eli Lilly. Both Simparica and Trifexis are administered on a monthly basis and are FDA approved for re-dosing after 30 days. The labeling on both companies' products directs consumers to repeat the treatment after one month.

Zoetis commissioned a study that compared the efficacy of both products after an initial administration of the competing flea and tick medications. Dogs were re-infested at days 0, 7, 14, 21, 28 and 35, without having re-dosed the dogs after 30 days, as directed by product labeling. Measurements of effectiveness were taken on these milestone days at 8, 12 and 24 hour intervals. Zoetis's advertising featured a chart that highlighted results of the study showing better efficacy by Simparica on day 35.  Zoetis argued that day 35 results were relevant to pet owners who may forget to re-dose the dogs at the end of the month.  According to Elanco, however, it was misleading to evaluate the efficacy of Trifexis on day 35 -- 5 days beyond the recommended re-dosing date.  Elanco also complained that Zoetis had "cherry picked" data points for its chart showing superior performance by Simparica at the 8 hour measurement point on certain milestone days, whereas the products had more equivalent effect at 12 and 24 hours on those days.

NAD concluded that it was misleading for Zoetis to advertise the day 35 results: "Testing the advertised products as they are intended to work, by following manufacturer's use instructions, provides the basis for a claim that a product is measurably better than its competitor because it does not materially distort the performance capability of competing products.... While consumers are free to disregard product instructions if they wish, advertisers have an obligation to follow product use instructions when conducting comparative performance testing for the purposes of claim support." NAD also agreed with Elanco that touting the better performance of Simparica at the 8 hour measurement point while ignoring the 12 and 24 hour measurements that showed more equivalent efficacy communicated the impliedly misleading message that Simparica was superior to Trifexis on the entire milestone day tested.

NAD recommended that Zoetis discontinue advertising claims based on comparative performance after 35 days, but observed that Zoetis could make a non-comparative claim that Simparica is effective for 35 days, particularly for consumers who forget to re-dose their dogs on a monthly basis. NAD also noted that the different product performance results at 8, 12 and 24 hour intervals on the milestone days could have been properly advertised as a speed-to-efficacy superiority claim, rather than one of overall efficacy.

The overarching lesson from the two NAD decisions discussed in Parts 1 and 2 of this post is that comparative advertising claims must be carefully and narrowly crafted.  Competitors identified in such claims will likely scrutinize the advertising for both express and implied messages that cannot be substantiated. The pitfalls are many, and different types of comparative advertising calls for different precautions. But following the do's and don'ts of NAD in Spectrum Brands and Zoetis will help: If specific models of competitive products are the intended comparison of an advertisement, do identify those specific products clearly and unambiguously.  Don't depict product varieties, use props or narrative content or tag lines that suggest a broader comparison is being made. If the comparative ad is based on performance testing of the competitive products, do test the products in accordance with labeling directions for use by consumers.   Don't cherry pick data from test results if doing so communicates a misleading message of overall superiority. And do carefully correlate the advertising claim to the specific aspect of superiority revealed by the product testing.

Related Categories:

Advertising

Firm Highlights

Insights

Minnesota Consumer-Fraud Enforcement: Disclaimers Won’t Cure Deception, and Penalties Can Add Up

Misleading advertising claims can lead to costly consequences. In State of Minnesota ex rel. Ellison v. Wall & Associates, Inc., No. A25-2064, 2026 WL 3118291 (Minn. App. Oct. 19, 2026), the Minnesota Court of Appeals recently affirmed a bench trial verdict against a tax-relief company and two executives for violations of the Minnesota Consumer Fraud Act (“MCFA”) and the Minnesota Deceptive Trade Practices Act (“MDTPA”). The decision, which affirmed a substantial restitution and civil penalty judgment, underscores the broad power of the Minnesota Attorney General to act against deceptive sales practices. The decision also offers practical lessons for businesses seeking to reduce liability risks in consumer-facing communications. Background Wall & Associates (“W&A”), a Virginia-based tax-relief company, marketed assistance to taxpayers seeking relief from outstanding federal and state tax liabilities, often with offers in compromise—agreements to settle tax liabilities for less than the amount owed. In its extensive advertising campaigns, W&A represented that its average client received a 90% reduction in their tax debt, that it was a local company with Minnesota offices, that it provided legal services, and that it would “Solve ALL Tax Problems.” In reality, W&A’s promises bore little resemblance to what many clients received. Most of W&A’s clients saw just a 9.5% reduction in federal tax debt and 1.2% in state tax debt. W&A had no permanent Minnesota offices. And W&A provided neither legal representation nor assistance with filing tax returns—those services required referrals to separate firms for an additional fee. All the while, W&A clients paid upfront and recurring fees, including during periods when W&A did no work on their cases. Minnesota Attorney General Keith Ellison sued W&A, its founder and owner Ernest Kenneth Wall, and its president and CEO Patrick Mark Yates, alleging violations of, among other laws, the MCFA and the MDTPA. Following a 12-day bench trial, the district court determined that W&A violated the MCFA and MDTPA through its false and embellished advertising. The district court also held Wall and Yates individually liable for those violations because they directed, participated in, and acquiesced in the violations. The district court ordered injunctive relief, $2.7 million in restitution (with Wall and Yates jointly and severally liable for $1.3 million), and civil penalties of $786,517 against W&A, $415,500 against Wall, and $207,750 against Yates. The district court also awarded over $2.5 million in attorneys’ fees and costs to the state. W&A, Wall, and Yates appealed to the Minnesota Court of Appeals, which affirmed the district court’s decision on October 19, 2026. Although W&A, Wall, and Yates challenged the judgment on numerous grounds, several highlights of the decision provide important takeaways for consumer-facing businesses. Individual Reliance Is Not Required for Statutory Liability W&A argued that Attorney General Ellison had to prove a causal nexus between each violation of the MCFA and MDTPA and the injury to a particular consumer to establish liability. In W&A’s view, this required proof that each injured consumer had personally relied on W&A’s false representation. The Court of Appeals rejected this argument based on the MCFA’s and MDTPA’s plain language, which requires no proof of actual deception or confusion by consumers. The Court of Appeals finally pointed to the Minnesota Supreme Court’s decision in State v. Minnesota School of Business, Inc., which held that when a defendant’s misrepresentations are directed at and affected “a broad group of consumers, proof of direct individual reliance is not required to establish a causal nexus between MCFA violations and the harm suffered by consumers.” 935 N.W.2d 124, 135 (Minn. 2019). The Court of Appeals affirmed, however, that a causal nexus is necessary to support an award of damages under the MCFA and MDTPA. In making that determination, district courts look to various factors, including whether the misrepresentations were “longstanding, pervasive, and widespread in communications directed to consumers,” whether the seller intended and understood that consumers would rely on the misrepresentations, and whether the information was of a kind on which consumers would typically rely. The Court of Appeals’ decision continues Minnesota School of Business’s broad interpretation of liability under the MCFA and the MDTPA. Coordinated marketing campaigns to a “broad group of consumers” may expose businesses to MCFA and MDTPA liability without customer-by-customer proof of injury. That said, a causal nexus remains an element of an MCFA and MDTPA claim, and businesses involved in litigation should build a clear record at trial and on appeal showing how each of the relevant factors bears on the causal-nexus inquiry. Contractual Disclaimers Are Not an Automatic Defense to a Misleading Pitch W&A next argued that disclaimers in its client contracts prevented consumers from claiming they had been misled by its advertising. Reiterating that individual reliance is not required under the MCFA and MDTPA, the Court of Appeals held that a contractual disclaimer does not necessarily defeat a claim based on a conflicting oral representation. And on the facts of this case, the Court of Appeals agreed with the district court that W&A’s contractual disclaimers were insufficient given the extensive misrepresentations by W&A and the unequal bargaining power between it and its customers. This holding confirms that contractual disclaimers are not a cure-all for misleading advertising or sales practices. Businesses should review the entire customer journey, including pre-contract representations, as those representations may survive a contractual disclaimer to the contrary. And if faced with litigation, businesses should build a strong record, both at trial and on appeal, showing why any disclaimer is effective in context. The State Has Broad Authority to Seek Restitution W&A also challenged Attorney General Ellison’s authority to seek restitution under the state’s parens patriae authority to protect residents’ collective interests, arguing that injury to only 228 Minnesotans did not affect a sufficiently substantial segment of the population. The Court of Appeals rejected a simple headcount approach, instead explaining that the state had a legitimate interest in protecting residents’ economic well-being as a whole. In any event, the Court of Appeals held that if restitution was not appropriate under the state’s parens patriae authority, then it would still be appropriate under the Attorney General’s enforcement powers under Minn. Stat. § 8.31. The decision reinforces that the broader and more sustained the deceptive advertising, the stronger the case for restitution to protect Minnesotans’ economic interests. Civil Penalties Accrue Per Violation, Not Per Defendant The Court of Appeals finally rejected W&A’s claim that the Attorney General’s enforcement powers under Minn. Stat. § 8.31 permit only civil penalties of up to $25,000 for each defendant. Rather, the Court of Appeals explained that penalties are limited to $25,000 per violation. Multiple violations can therefore produce substantially greater penalties. The Court of Appeals also rejected the argument that restitution made penalties unnecessary: repaying consumers does not eliminate the need to address gains from deceptive conduct and deter future violations. Final Takeaways Align every consumer-facing communication. Broad and extensive marketing campaigns can expose businesses to stronger enforcement standards under the MCFA and MDTPA, making it critical that consumer communications remain accurate and consistent from the first advertisement through the final sale. Plan for layered enforcement exposure. Penalties under the MCFA and MDTPA can add up quickly: W&A, Wall, and Yates ultimately faced more than $6 million in civil penalties, restitution, and attorneys’ fees. The decision continues a line of Minnesota cases recognizing the Attorney General’s broad consumer-protection authority. Details matter. Although the Attorney General’s enforcement power is broad, it is not boundless. As the Court of Appeals explained, issues of causation, the effectiveness of contractual disclaimers, and the availability of restitution and civil penalties all turn on the specific facts of the case. Effective advocacy at trial and on appeal is critical to developing the facts relevant to liability and damages.